---
title: Austrian Reimbursement for Medical Devices: The Payer System
description: How Austrian social insurance, hospital budgets, and the LKF system reimburse medical devices — and what MedTech founders need to prepare.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: Austrian reimbursement medical devices
canonical_url: https://zechmeister-solutions.com/en/blog/austrian-reimbursement-medical-devices
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Austrian Reimbursement for Medical Devices: The Payer System

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **Austrian reimbursement for medical devices runs on two parallel tracks: inpatient care is financed through the LKF system administered by the federal states, while outpatient care is paid by statutory social insurance carriers led by ÖGK. CE marking is the price of entry, not the finish line — getting listed, coded, and actually paid requires its own evidence and stakeholder work.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- Austria has statutory social health insurance covering virtually the entire population, with ÖGK (Österreichische Gesundheitskasse) as the dominant carrier after the 2020 merger. 
- Inpatient care is reimbursed via the LKF (Leistungsorientierte Krankenanstaltenfinanzierung) system, Austria's performance-oriented hospital financing DRG variant, operated at the level of the nine federal states (Länder).
- Devices used during an inpatient stay are usually absorbed into the LKF flat fee for the corresponding MEL (Medizinische Einzelleistung) procedure code — there is rarely a separate device payment.
- Outpatient medical aids and durable devices run through the Heilbehelfe und Hilfsmittel catalogue of the social insurance carriers, with patient co-payments and strict listing requirements. 
- CE marking under MDR is a prerequisite for any reimbursement conversation, but it does not guarantee listing, coding, or adoption.
- For startups, the realistic path is: CE mark first, then hospital pilot contracts, then work toward MEL code recognition or inclusion in the Hilfsmittel catalogue.

## Why Austrian reimbursement matters for MedTech founders

Austria is small — around nine million people — but it punches well above its weight as a MedTech beachhead. The regulatory environment is European, the hospital system is sophisticated, clinical partners in Vienna, Graz, Linz, and Innsbruck are accessible, and the payer landscape, while bureaucratic, is navigable in German. For founders building from the DACH region, Austria is often the first market where a CE-marked device actually generates revenue.

The catch is that CE marking and getting paid are two different problems. A notified body cares whether your device meets the General Safety and Performance Requirements in Annex I of Regulation (EU) 2017/745. A payer cares whether your device delivers outcomes that justify the price — and whether anyone in their reimbursement catalogue knows how to code it. Founders who assume "CE equals sales" lose six to twelve months realising the payer conversation is a separate project.

Tibor's firm is based in Graz. Over the last decade he has walked a dozen startups through the Austrian payer maze and seen the same pattern: teams with excellent technical files who had not spent an hour thinking about LKF codes or ÖGK listing criteria. This post is the primer he wishes every founder read before their first hospital meeting.

## What MDR actually says about reimbursement

Nothing. The MDR is silent on pricing, reimbursement, and payer decisions. Regulation (EU) 2017/745 governs whether a device can be placed on the EU market (Article 5) and how its intended purpose is defined (Article 2(12)). Reimbursement is a national competence — each Member State runs its own health insurance and hospital financing system.

What MDR does require, however, shapes the evidence you will also need for payers:

- **Clinical evaluation under Article 61 and Annex XIV** obliges the manufacturer to generate or compile clinical data demonstrating safety, performance, and acceptable benefit-risk. Payers routinely reuse this evidence when assessing whether to reimburse.
- **Post-market surveillance under Articles 83 to 86** and post-market clinical follow-up under Annex XIV Part B generate the real-world data that Austrian payers increasingly expect to see before adding a device to a catalogue.
- **Intended purpose under Article 2(12)** — *"intended purpose means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation"* — directly determines which procedure code applies and therefore how the device is paid.

In other words, reimbursement is not regulated by MDR, but your MDR file is the foundation of your reimbursement dossier. Treat them as one evidence programme, not two.

## The Austrian payer landscape in plain language

There are three money flows MedTech founders need to understand.

**1. Inpatient hospital care — LKF system.** When a patient is admitted to a public or private non-profit hospital (Fondskrankenanstalt), the stay is reimbursed through LKF, Austria's points-based DRG variant. The stay is coded with one or more MEL (Medizinische Einzelleistung) procedure codes plus a main diagnosis, and the hospital receives an LKF point value that is converted into euros by the state health fund (Landesgesundheitsfonds). 

For a device manufacturer, the key question is: *does an existing MEL code cover my procedure?* If yes, and the hospital already performs that procedure, you are selling into an existing budget — you do not need a new reimbursement code, you need to convince the hospital department and the purchasing group that your device improves the procedure enough to absorb the cost. If no MEL code exists for your intervention, you face a much harder problem: getting a new code created by the Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz (BMSGPK). 

**2. Outpatient care — social insurance carriers.** Statutory social insurance is dominated by ÖGK (Österreichische Gesundheitskasse), formed in 2020 by merging the nine former regional Gebietskrankenkassen. Alongside ÖGK sit smaller carriers such as BVAEB (civil servants and railways) and SVS (self-employed and farmers). 

For devices used in outpatient settings — home-use devices, durable medical equipment, assistive technology, certain diagnostics — the relevant framework is the *Heilbehelfe und Hilfsmittel* provision, where the carrier reimburses part of the cost, the patient pays a co-payment, and the device must meet listing criteria set by the carrier. 

**3. Private top-up insurance.** A minority of Austrians hold private supplementary insurance (Zusatzversicherung) that pays for upgraded hospital rooms and occasionally specific uncovered treatments. This is a small revenue pool for most MedTech startups but can open doors for premium devices in high-end clinics.

## A worked example: a surgical navigation add-on

Suppose a Graz-based startup has CE-marked a Class IIb surgical navigation accessory that reduces operating time for a specific orthopaedic procedure by twelve minutes on average. List price: EUR 450 per single-use cartridge.

The founder's reimbursement plan:

1. **Identify the MEL code.** The underlying orthopaedic procedure already has an MEL code and an LKF point value. The navigation cartridge is a consumable used during that procedure. There is no separate reimbursement — the hospital absorbs the EUR 450 into its existing LKF payment for the procedure.
2. **Build the hospital business case.** The hospital's department head cares about throughput, complication rates, and theatre turnover. Twelve minutes saved per case at a theatre cost of roughly EUR 15–25 per minute is EUR 180–300 in recovered capacity. If complication rates also drop, the case for absorbing EUR 450 becomes defensible — but only if the clinical data is specific and Austrian-relevant.
3. **Target the decision-making unit.** In an Austrian public hospital, buying this cartridge means convincing the clinical lead (who decides whether the device is used), the MedTech commission or purchasing group (who approves the procurement process), and often the hospital pharmacy or materials management (who handle the framework agreements). Missing any of these three stalls the deal.
4. **Pilot first, framework agreement second.** The realistic first year is two or three pilot sites running the cartridge on a limited case series. The clinical data from those pilots becomes both PMCF evidence for MDR compliance under Annex XIV Part B and commercial evidence for the hospital purchasing conversation. One file, two audiences.

This is the pattern Tibor sees work most often: pick an existing MEL code, sell into the existing budget, let hospital pilots generate both regulatory and commercial evidence. Startups who try to get a new code created before first revenue almost always run out of runway first.

## The Subtract to Ship playbook for Austrian reimbursement

If you strip the Austrian payer problem down to what actually moves the needle for a startup, you are left with six moves.

**1. Freeze your intended purpose before anything else.** Under Article 2(12) your intended purpose defines your device and, by extension, which procedure code it maps to. Changing it later means redoing clinical evaluation *and* reopening the reimbursement conversation. Write it once, write it carefully, and stress-test it against the MEL catalogue before you lock it.

**2. Map your procedure to an existing MEL code.** Before you build a reimbursement strategy, spend two days with the current LKF/MEL documentation and a friendly hospital controller. Find out whether your use case already has a code. If yes, your job is commercial. If no, you need a much longer-term strategy and probably a clinical champion willing to push for code creation.

**3. Use one evidence programme for MDR and payers.** Your clinical evaluation report, your PMCF plan, your PMS data, and your Austrian hospital pilot data should be one coherent body of evidence. Designing a second, parallel "health economics" programme from scratch is a classic startup mistake that burns cash for no reason.

**4. Pilot with two or three Austrian hospitals on framework contracts.** Direct framework agreements with individual hospitals are the fastest path to first revenue. Austrian teaching hospitals in Vienna, Graz, Innsbruck, and Linz all have MedTech innovation processes — slow, but real. Use them.

**5. Budget realistically.** Expect 6 to 12 months from CE mark to first paid use, and 18 to 36 months before framework agreements become repeatable. Any pitch deck claiming faster is selling optimism.

**6. Separate inpatient and outpatient strategies early.** If your device straddles both — for example, a home-use continuation of a hospital-initiated therapy — you have two payer processes running in parallel. Do not treat them as one.

## Reality Check

Honest answers to these questions will tell you where you actually stand.

1. Can you name the single most likely MEL code your procedure would fall under, or are you guessing?
2. Have you spoken to at least one Austrian hospital controller about how your device would be coded and paid?
3. Is your intended purpose frozen, written, and matched to your clinical evaluation — or is it still drifting between pitch decks?
4. If your device is outpatient, do you know whether it qualifies as a Heilbehelf or Hilfsmittel under current ÖGK criteria?
5. Does your clinical evaluation plan generate data that will satisfy both your notified body *and* your first hospital customer?
6. How many months of runway do you have, and does that cover 12 months of reimbursement work *after* CE mark?
7. Do you have an Austrian clinical champion willing to push your case inside at least one hospital's MedTech commission?
8. If the answer to the MEL code question is "no existing code fits," do you have a Plan B that does not require new code creation?

## Frequently Asked Questions

**Does a CE mark under MDR automatically mean I get reimbursed in Austria?**
No. CE marking is a necessary precondition but not a reimbursement decision. Austrian payers decide independently based on clinical evidence, cost, and whether a suitable code exists. Plan for reimbursement as a separate workstream that starts in parallel with your notified body submission.

**Is ÖGK a single national payer or regional?**
ÖGK is national since the 2020 merger of the former regional Gebietskrankenkassen, but it still operates with regional offices and some regional variation in practice. Alongside ÖGK sit smaller carriers like BVAEB and SVS. 

**What is the difference between LKF and MEL?**
LKF is the overall performance-oriented hospital financing system. MEL (Medizinische Einzelleistung) is the catalogue of individual procedure codes used within LKF. Each MEL has an LKF point value that determines the euro payment to the hospital.

**Can I sell to private Austrian hospitals outside the LKF system?**
Yes, a limited number of purely private hospitals operate outside Fondskrankenanstalt funding. They are price-sensitive in different ways and often faster decision-makers, but the volume is small compared to the public system.

**Do I need a separate health economic evaluation for Austria?**
Not always. For devices slotting into existing MEL codes, a well-written MDR clinical evaluation plus a hospital-level business case is often enough. For genuinely new interventions, yes — a formal HEE becomes part of the conversation.

**Should I hire an Austrian reimbursement consultant?**
For most startups, no — not initially. Spend your first few thousand euros on one or two structured conversations with a hospital controller and a friendly ÖGK contact. Hire specialist help only once you know which specific question you need answered.

## Related reading
- [Health Insurance Reimbursement in Europe](/blog/health-insurance-reimbursement-europe) — the continental overview Austria sits inside.
- [German Reimbursement for Medical Devices](/blog/german-reimbursement-medical-devices) — the neighbouring payer system, useful for DACH expansion.
- [HTA Submissions for Medical Devices](/blog/hta-submissions-medical-devices) — when formal technology assessment enters the picture.
- [MedTech Business Model Analysis](/blog/medtech-business-model-analysis) — how reimbursement shapes your business model, not the other way round.
- [MedTech Go-To-Market Strategy](/blog/medtech-go-to-market-strategy) — sequencing CE mark, pilots, and framework contracts.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 2(12), 5, 61, 83–86, Annex XIV.
2. Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz — LKF-Modell documentation. 
3. ÖGK — Leistungen und Heilbehelfe/Hilfsmittel framework documentation. 

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*